Who Paid My Doc
Ana Becerra
Farmington, CT Medical Doctor
NPI 1578116703 CMS profile 11557644
Uconn Health Im Associates, 263 Farmington Ave, Op 2 West, Farmington, CT 06032
General payments
$38,118
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Ana Becerra of Farmington, CT is reported in the CMS Open Payments database as having received $38,118 across 75 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $31,926 | 23 | |
| 2024 | General | $5,040 | 41 | |
| 2023 | General | $1,152 | 11 |
Beside peers
- Ana Becerra
- Connecticut median
- Middle half of Connecticut
- National median
In program year 2025, general payments to Ana Becerra were reported at $31,926. Among 12,665 Connecticut profiles paid that year, the median was $167 and the middle half received between $54 and $639.
Show as a table
| Year | Ana Becerra | Connecticut median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $163 | $50–$671 | $163 |
| 2020 | $0 | $111 | $33–$382 | $114 |
| 2021 | $0 | $124 | $39–$443 | $132 |
| 2022 | $0 | $138 | $45–$535 | $149 |
| 2023 | $1,152 | $148 | $47–$556 | $160 |
| 2024 | $5,040 | $157 | $49–$599 | $164 |
| 2025 | $31,926 | $167 | $54–$639 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
89
Drug cost
$22,395
Branded share of claims
30.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 14 | $21,779 | |
| Atorvastatin Calcium | Generic | 15 | $201 | |
| Lisinopril | Generic | 15 | $135 | |
| Isosorbide Mononitrate Er Isosorbide Mononitrate | Brand | 13 | $134 | |
| Carvedilol | Generic | 20 | $104 | |
| Losartan Potassium | Generic | 12 | $42 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 30,207 Part D prescribers listed as Student in an Organized Health Care Education/Training Program; they describe a distribution and say nothing about conduct.
Records
75 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.